danuglipron
Small moleculeexperimental
Clinical trial activity
19 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2017 (NCT03309241)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1- Mol. weight
- 555.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4518483 ↗
Also known as
- pf-06882961
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06910839 | Phase 1 | Mar 13, 2025 | Pfizer |
| NCT06541678 | Phase 1 | Dec 16, 2024 | Pfizer |
| NCT06567327 | Phase 1 | Aug 28, 2024 | Pfizer |
| NCT06568731 | Phase 1 | Aug 23, 2024 | Pfizer |
| NCT05093205 | Phase 1 | Oct 25, 2021 | Pfizer |
| NCT04889157 | Phase 1 | Jul 7, 2021 | Pfizer |
| NCT04839393 | Phase 1 | Apr 5, 2021 | Pfizer |
| NCT04707313 | Phase 2 | Jan 29, 2021 | Pfizer |
| NCT04616027 | Phase 1 | Jan 13, 2021 | Pfizer |
| NCT04604496 | Phase 1 | Dec 30, 2020 | Pfizer |
| NCT04621227 | Phase 1 | Dec 15, 2020 | Pfizer |
| NCT04617275 | Phase 2 | Dec 3, 2020 | Pfizer |
| NCT04616339 | Phase 1 | Nov 4, 2020 | Pfizer |
| NCT04552470 | Phase 1 | Oct 26, 2020 | Pfizer |
| NCT04495140 | Phase 1 | Jul 22, 2020 | Pfizer |
| NCT03985293 | Phase 2 | Jul 15, 2019 | Pfizer |
| NCT03538743 | Phase 1 | Jun 25, 2018 | Pfizer |
| NCT03492697 | Phase 1 | Apr 30, 2018 | Pfizer |
| NCT03309241 | Phase 1 | Oct 17, 2017 | Pfizer |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 19 | 19 | 2 | 2017 |
1 organizations
Page 1 / 1